Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
This is a completed Phase 3 RCT registration with no posted results; the primary endpoint (overall survival) and outcomes are not reported in this registry record, making it impossible to assess efficacy or safety.
This is an ongoing Phase 3 trial registration with no results posted; the study is actively recruiting and has not yet reported efficacy or safety outcomes.
Phase 3 randomized trial of ifinatamab deruxtecan versus physician's choice in relapsed SCLC; registry record with no results posted, so efficacy and safety remain unreported.